Results from a phase 1/2 study from Nanoscope Therapeutics were presented at the 2021 ASRS meeting.
The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.
Review top news and interview highlights from the week ending October 15, 2021.
Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.
The study follows Legend Biotech’s initial success with cilta-cel, whose PDUFA date is set for November 2021.